Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Only a minority of lung cancers are resectable at diagnosis, and many of these will
eventually relapse. Adjuvant chemotherapy in this setting has a modest survival advantage …
eventually relapse. Adjuvant chemotherapy in this setting has a modest survival advantage …
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of
patients with locally advanced unresectable and metastatic non-small cell lung cancer …
patients with locally advanced unresectable and metastatic non-small cell lung cancer …
Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
Y Wang, S Huang, X Feng, W Xu, R Luo, Z Zhu… - Frontiers in …, 2023 - frontiersin.org
The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of
non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …
non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …
Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
X Wu, YF Chau, H Bai, X Zhuang, J Wang… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell
lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and …
lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and …
Adjuvant and neo‐adjuvant immunotherapy in resectable non‐small cell lung cancer (NSCLC): Current status and perspectives
Z Xu, Z Zou, X Hao, P **ng, J Li - Cancer Innovation, 2023 - Wiley Online Library
Surgery followed by adjuvant chemotherapy is the standard of care for selected patients with
early‐stage or locally advanced non‐small cell lung cancer (NSCLC). However, many of …
early‐stage or locally advanced non‐small cell lung cancer (NSCLC). However, many of …
[HTML][HTML] Pathological response and immune biomarker assessment in non-small-cell lung carcinoma receiving neoadjuvant immune checkpoint inhibitors
Simple Summary Recently, the US Food and Drug Administration (FDA) approved
neoadjuvant immunotherapy plus chemotherapy for the treatment of resectable non-small …
neoadjuvant immunotherapy plus chemotherapy for the treatment of resectable non-small …
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review
SC Efil, B Bilgin, F Ceylan, H Karakaş… - Journal of Oncology …, 2024 - journals.sagepub.com
Objective The objective of this article is to review the efficacy, safety, and evidence for
current use and potential future uses of immune-checkpoint inhibitors (ICIs) in the …
current use and potential future uses of immune-checkpoint inhibitors (ICIs) in the …
[PDF][PDF] Biomarkers under investigation for neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer
Y Söyler, Ü Yılmaz - AME Surg J, 2022 - researchgate.net
The 5-year relative survival of non-small cell lung cancer (NSCLC) is still low even in
patients with resectable disease due to local or distant recurrences after surgery. Novel …
patients with resectable disease due to local or distant recurrences after surgery. Novel …
[PDF][PDF] 非小细胞肺癌的新辅助免疫治疗: 当前理念和未来方向
王婧怡， 钟雨玲， 邬麟 - 肿瘤, 2024 - tumorsci.org
肺癌是**乃至全世界范围内死亡率最高的恶性肿瘤, 其中非小细胞肺癌(non-small cell lung
cancer, NSCLC) 是其最常见的组织学类型. 手术是Ⅰ-ⅢA 期NSCLC 患者的重要治疗手段 …
cancer, NSCLC) 是其最常见的组织学类型. 手术是Ⅰ-ⅢA 期NSCLC 患者的重要治疗手段 …